Page last updated: 2024-10-30

leflunomide and Pneumoconiosis

leflunomide has been researched along with Pneumoconiosis in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Pneumoconiosis: A diffuse parenchymal lung disease caused by inhalation of dust and by tissue reaction to their presence. These inorganic, organic, particulate, or vaporized matters usually are inhaled by workers in their occupational environment, leading to the various forms (ASBESTOSIS; BYSSINOSIS; and others). Similar air pollution can also have deleterious effects on the general population.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yasmine, M1
Kaouther, M1
Dhia, K1
Hanene, F1
Wafa, T1
Dorra, BN1
Wafa, H1

Other Studies

1 other study available for leflunomide and Pneumoconiosis

ArticleYear
Treatment with Rituximab in Rheumatoid Pneumoconiosis: A Case Report.
    Current drug safety, 2023, Volume: 18, Issue:3

    Topics: Aged; Arthritis, Rheumatoid; Caplan Syndrome; Humans; Leflunomide; Male; Pneumoconiosis; Rituximab

2023